Dobetin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dobetin

Dobetin is a pharmaceutical preparation utilized for the essential replenishment of Vitamin B12 in the body, primarily categorized as an Antianemic Preparation due to its critical role in red blood cell maturation.

Property Description
Active ingredient Cyanocobalamin (Vitamin B12)
Form Sterile Solution for Injection
Pharmacological class Hematopoietic Agent / Water-soluble Vitamin
Common use Replenishment Therapy for B12 deficiency
Origin Synthetic cobalamin form

What Type of Medicine is Dobetin (Cyanocobalamin)?

The medicine contains the single active ingredient, Cyanocobalamin, which is the chemical name for a specific form of Vitamin B12 (Cobalamin). It is officially classified as a Hematopoietic Agent and an Antianemic Preparation within the international therapeutic classification system. This product, which is often a prescription-only medicine, is clinically recognized for its reliable action in providing systemic B12 to support the body's ability to produce necessary blood components when a deficiency is confirmed.

Composition, Origin, and Physical Form of the Preparation

The core component, Cyanocobalamin, is an essential micronutrient derivative that is produced as a synthetic cobalamin form. This synthetic origin allows for a stable, high-purity formulation. Dobetin is manufactured as a sterile Aqueous Solution designed for Parenteral administration. This injectable format is often chosen in typical use scenarios for patient groups, such as those with malabsorption syndromes, where oral intake is ineffective, ensuring maximum and reliable absorption directly into the bloodstream.

General Purpose and Biological Rationale for Use

The general purpose of the preparation is to serve as a high-efficiency source of the vitamin, supporting key biological pathways. Cyanocobalamin is required as a co-factor for processes that govern the development of red blood cells and the health of the nervous system. The substance is necessary for the maintenance of the nervous system and the production of red blood cells, confirming its core therapeutic value.

What side effects are possible with Dobetin ?

Possible Side Effects and Safety Information

The safety profile of Cyanocobalamin injection (Dobetin) is based on the classification of adverse reactions documented in official regulatory labeling. These reactions are grouped by the physiological system affected and by their potential severity.


Documented Adverse Reactions and Serious Events

Adverse reactions are classified within several System-Organ Classes. Reactions affecting the skin and subcutaneous tissue disorders may include a transitory exanthema (rash), urticaria, itching (pruritus), and mild acneiform eruptions. A mild transient diarrhea is also documented under gastrointestinal disorders.

Serious adverse reactions reported in official sources include those related to hypersensitivity, such as anaphylactic shock and death. The cardiac disorders section notes the occurrence of pulmonary edema and congestive heart failure during initial therapy. Events related to the vascular system include documented cases of peripheral vascular thrombosis.


Safety Constraints and Time-Related Patterns

Specific safety constraints are tied to certain patient groups. Cyanocobalamin is contraindicated in patients with a known hypersensitivity to the drug or to cobalt. It is also specifically contraindicated for individuals with early Leber's hereditary optic neuropathy due to the risk of severe optic atrophy.

Certain risks are associated with the initial phase of intensive treatment for severe megaloblastic anemia, including potentially fatal hypokalemia and subsequent cardiac arrhythmias. The regulatory labeling also specifies a diagnostic constraint: administration of the medicine may mask the diagnosis of an underlying folate deficiency, which is a key consideration for its use.

Overdose and Emergency Response

Overdose and When to Seek Help

The active component of Dobetin, Cyanocobalamin, is a water-soluble vitamin officially characterized by low inherent toxicity. Due to this low toxicity profile, regulatory labeling generally indicates that an acute overdose is unlikely to result in severe or life-threatening manifestations.

Documented Overdose Presentations

Official regulatory documents note that signs of excessive exposure are typically mild and transient, including:

  • Cutaneous reactions such as transient rubor (redness or flushing) and pruritus (mild itching).
  • Gastrointestinal disturbance such as temporary diarrhea.

Management procedures are officially limited to symptomatic and supportive treatment, as no specific antidote is known for cyanocobalamin overdose.

When Immediate Medical Help is Required

The mandate to seek urgent medical attention is focused on identifying severe, non-toxic events. Immediate medical attention must be sought if any clinical signs or symptoms suggest a severe hypersensitivity reaction, such as difficulty breathing, swelling of the face or throat, or an extensive rash. These events represent an acute medical emergency and require immediate care regardless of the dose received. The official overdose profile does not detail specific, heightened risks for populations such as children or the elderly.

Therapeutic Uses of Dobetin

What Dobetin Treats: Main Uses and Benefits

The therapeutic role of cyanocobalamin is relevant when supportive symptom management is appropriate for conditions associated with symptoms related to systemic imbalance and certain neurological symptoms. It is used in situations involving distressing symptoms such as symptoms related to physical discomfort, symptoms related to systemic imbalance, and symptoms that interfere with daily functioning. This medicine is applied across domains where additional symptomatic support is needed, often utilized during phases when symptoms become more noticeable.


Quick Fact: Supportive Relief for Symptomatic Discomfort

Dobetin is commonly used when short-term symptomatic assistance is needed in general clinical contexts marked by significant symptomatic burden. It supports the patient during difficult episodes by easing distress and may assist with managing low energy. The symptomatic support provided is relevant for conditions characterized by periods of heightened symptoms, conditions involving episodic or fluctuating manifestations, and is applied in scenarios where symptoms create noticeable physiological strain. It contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory criteria for Dobetin (Cyanocobalamin injection) define the specific populations permitted to use the medicine and those for whom use is strictly prohibited or restricted.

Contraindicated Populations (Must Not Use)

Classification Population Group Regulatory Basis
Absolute Contraindication Patients with known sensitivity to Cobalt or Cyanocobalamin (Vitamin B12).
Disease-Specific Exclusion Patients with Early Leber's Disease (hereditary optic nerve atrophy).

Eligibility and Conditional Use

Permitted Groups: Use is established for Adults and Children with confirmed Vitamin B12 deficiency, including those with Pernicious Anemia or malabsorption syndromes like post-gastrectomy conditions.

Use Restrictions:

  • Renal Impairment: Caution is necessary in patients with impaired kidney function, particularly with prolonged use, due to the documented risk of aluminum accumulation from some parenteral formulations.
  • Infants/Neonates: Caution is required if the formulation contains Benzyl Alcohol, which is linked to a serious adverse syndrome in premature infants.
  • Undiagnosed Anemia: The medicine should not be used if the type of anemia is not confirmed, as it can mask a Folic Acid Deficiency, allowing neurological damage to progress.
  • Pregnancy/Lactation: Use is generally acceptable and determined by clinical need to address the increased Vitamin B12 requirements during these periods.

The regulatory documents clearly define who can and cannot use the medicine, focusing on intrinsic patient factors and specific high-risk clinical states.

What should I know about interactions with other medicines?

The official regulatory profile for Dobetin (Cyanocobalamin) documents interactions primarily involving substances that interfere with its therapeutic action or significantly reduce the body's absorption and systemic exposure. These patterns are generally classified as absorption-altering effects or pharmacodynamic interference, rather than traditional metabolic enzyme interactions.

Interacting Substance/Class Official Regulatory Effect
Chloramphenicol May antagonize the intended hematopoietic response.
Metformin Associated with decreased serum B12 levels due to reduced intestinal uptake.
Acid-Reducing Medicines May impair the cleavage of the vitamin from food sources, potentially affecting absorption.
Aminoglycosides, Colchicine Documented to impair the absorption of Vitamin B12 in the gastrointestinal tract.
Nitrous Oxide Known to cause inactivation of the vitamin (functional deficiency risk).
High-Dose Folic Acid May mask the hematologic symptoms of B12 deficiency without preventing neurological damage.

A mandatory timing constraint exists for Vitamin C (ascorbic acid). High doses must be administered at least one hour apart from oral B12 preparations, as regulatory documents note the potential for destruction of the vitamin. Separately, heavy alcohol intake consumed chronically for more than two weeks is documented to induce the malabsorption of Vitamin B12. A population-specific constraint notes that patients with impaired kidney function may face a risk of aluminum accumulation with prolonged parenteral use of certain B12 formulations.

Mechanism of Action

Dobetin, containing hydroxocobalamin, functions as a cobalt-containing corrinoid that, once administered, binds to plasma proteins, primarily transcobalamin II (TC-II), for transport into target cells, including hematopoietic and neural tissues. Intracellularly, hydroxocobalamin is converted into the two active coenzyme forms: methylcobalamin (MeCbl) and 5-deoxyadenosylcobalamin (AdoCbl).

MeCbl acts as an essential cofactor for the cytoplasmic enzyme methionine synthase. This interaction facilitates the transfer of a methyl group from 5-methyltetrahydrofolate (5-MeTHF) to homocysteine, thereby generating methionine and regenerating tetrahydrofolate (THF). The subsequent production of S-adenosylmethionine (SAM) is crucial for numerous methylation reactions, including those involving DNA, RNA, proteins, and lipids.

Simultaneously, AdoCbl serves as a cofactor for the mitochondrial enzyme methylmalonyl-CoA mutase. This enzyme catalyzes the isomerization of L-methylmalonyl-CoA to succinyl-CoA, an intermediate in the tricarboxylic acid (TCA) cycle. This molecular pathway is indispensable for the proper metabolism of odd-chain fatty acids and branched-chain amino acids. The system-level physiological consequence of these restored enzymatic activities is the modulation of DNA synthesis, myelin sheath integrity, and hematopoiesis through enhanced metabolic flux.

Dosage and Administration Information

How to Use Dobetin — Official Administration Guidelines

Dobetin (Cyanocobalamin) is an injectable solution with usage instructions dictated by regulatory guidelines, establishing specific routes, doses, and schedules for administration.


Administration Scope

Entity Detail
Route of administration Intramuscular (IM) injection or Deep Subcutaneous (SC) injection.
Dosing schedule Initial Correction (Loading Phase): 1,000 mcg IM/SC daily for 6 to 7 days, or 250 to 1,000 mcg IM on alternate days for 1 to 2 weeks.
Maintenance: 1,000 mcg IM/SC monthly is the common regimen for long-term use.
Preparation requirements The parenteral solution should be warmed to body temperature prior to administration for patient comfort. The solution must be visually inspected for particulate matter.
Age-group administration rules The standard adult dosage schedules are stated as suitable for children (Pediatric Population).

Instruction Classifications

Entity Detail
Administration method type Parenteral Injection.
Frequency pattern Daily/Alternate Days (Initial) to Monthly (Maintenance).
Regulatory basis National and International Pharmaceutical Standards.
Use-context constraints Avoid the Intravenous (IV) route for deficiency treatment due to the rapid excretion and loss of the vitamin.

Resulting Procedural Structure

The official usage sequence dictates that the administration must be carried out under trained professional supervision using the IM or SC route. This therapy follows a standard two-phase protocol, beginning with a high-frequency loading dose to rapidly restore levels and concluding with a fixed, low-frequency monthly maintenance dose, which is often required for the remainder of the patient's life for conditions involving permanent malabsorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dobetin (Cyanocobalamin)

This overview describes the research landscape for Dobetin (injectable cyanocobalamin), focusing on the types of studies conducted and what the evidence suggests, without offering clinical advice or treatment recommendations. The evidence discussed here comes only from official regulatory sources and peer-reviewed scientific literature.


Evidence for Initial Use in Overt B12 Deficiency

The role of the injection in addressing overt Vitamin B12 deficiency—meaning cases where patients exhibit clear symptoms like anemia or neurological issues—is documented in clinical practice and regulatory experience. Evidence includes older, extensive observational studies and a large body of clinical experience that research describes the condition's progression and response to replacement therapy.

More recent research, including Randomized Controlled Trials (RCTs), has focused on comparing the parenteral (injection) route with high-dose oral vitamin B12. These trials primarily evaluated the ability of each route to correct low B12 and metabolic biomarkers (such as MMA). What remains uncertain is the full extent of long-term recovery from neurological symptoms when the deficiency was present for a long time before diagnosis.


Evidence for Long-Term Maintenance in Malabsorption Syndromes

For individuals with chronic conditions such as pernicious anemia or those who have had gastrointestinal surgery that prevents natural B12 absorption, Dobetin was studied for long-term maintenance therapy. Research examining this phase includes long-term observational cohort studies that followed patient groups over years, monitoring the continuous maintenance of stable blood markers and the prevention of deficiency relapse.

Comparative trials have explored whether the standard injectable maintenance schedule maintains blood stability similarly to alternative, high-dose oral maintenance regimens. However, long-term comparative evidence is limited for the durability and consistency of the injectable route versus the oral route over multiple decades.


Research on Borderline or Subclinical B12 Levels

This section covers the research conducted when B12 levels are low but the patient does not have severe, overt symptoms—a condition often called subclinical deficiency. This area relies mainly on Randomized Controlled Trials (RCTs), where B12 administration was studied for its impact compared to placebo or no treatment.

Trials consistently reported that B12 administration was associated with a reduction or normalization of the metabolic biomarkers in the blood. However, when these studies monitored changes in functional outcomes (like cognitive performance or mobility), findings were often mixed or inconsistent.

Key Studies & References

  1. Cyanocobalamin - StatPearls - NCBI Bookshelf (Review of Indications and Practice)
  2. Evidence review for vitamin B12 replacement (Clinical Effectiveness and Cost-effectiveness Review)
  3. Cyanocobalamin (Vitamin B12): MedlinePlus Drug Information (General Overview)
  4. Cyanocobalamin Injection: MedlinePlus Drug Information (Injection-Specific Overview)

Frequently Asked Questions (FAQ)

Common questions about Dobetin (FAQ)

Q: Is Dobetin the same type of medicine as [similar drug name]?

A: Dobetin contains the active ingredient Cyanocobalamin, which is a common synthetic form of Vitamin B12. Regulatory information confirms that other forms of B12, such as Hydroxocobalamin, are also described in authoritative texts for similar therapeutic uses.

Q: How long does it usually take to notice an effect from Dobetin?

A: The official protocol is designed to rapidly restore Vitamin B12 levels in the body, with the highest concentration in the bloodstream reached shortly after injection. While the speed of the body’s physiological response (like the production of red blood cells) is described as rapid, the timeframe for a patient to notice overall symptom improvement is a complex clinical outcome.

Q: What are the research findings regarding Dobetin's long-term use?

A: Studies and regulatory documents describe the intended role of maintenance therapy for long-term use in patients with permanent malabsorption issues. However, official information also notes that for correctible or temporary causes of deficiency, the evidence for the benefit of continuous long-term use may not be fully established.

Q: Is Dobetin considered a long-term treatment?

A: Yes, for certain chronic conditions, the official treatment protocol is considered long-term. This involves an initial correction phase followed by a fixed, low-frequency monthly maintenance dose. This maintenance phase is often administered long-term for conditions that cause a permanent inability to absorb Vitamin B12.

Q: Why do some people say they feel tired after starting Dobetin?

A: Extreme fatigue and tiredness are commonly documented symptoms of the underlying Vitamin B12 deficiency that the medicine is used to treat. While tiredness is not listed as a common adverse reaction, official information indicates that improvement in fatigue is consistent with the expected functional benefits described in regulatory information.

Q: What are the potential interactions between Dobetin and herbal supplements?

A: Regulatory documents prioritize listing interactions with specific pharmaceuticals. Official product information notes that due to limited testing, the effects of herbal remedies and supplements on this medicine are not fully documented in regulatory texts.

Q: What happens if Dobetin is accidentally exposed to high heat?

A: The official product description notes that while Cyanocobalamin is chemically stable, its active coenzyme forms are very unstable and sensitive to light. Therefore, prolonged exposure to high heat outside of the documented storage conditions could potentially compromise the quality and effectiveness of the solution.

Q: Does Dobetin interact with common pain relievers like ibuprofen?

A: Regulatory documents do not list a specific pharmacological interaction between the Cyanocobalamin injection and Ibuprofen or other common nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: Is it okay to drink coffee while taking Dobetin?

A: According to official product information, there are no known interactions documented between the injectable form of this medicine and the consumption of coffee or caffeine-containing products.

Q: Are there any specific foods to avoid when using Dobetin?

A: The injectable form of this medicine bypasses the need for intestinal absorption. Therefore, no general dietary restrictions are typically mandated in official sources when receiving the injection.

Q: Does Dobetin affect my ability to drive?

A: Official safety documents generally state that this medicine does not usually affect the ability to drive or operate machinery.

Q: Is there a generic version of Dobetin available?

A: Yes, the active ingredient, Cyanocobalamin Injection, is available as a generic product. Regulatory product listings confirm the availability of this generic form in various concentrations and presentations.

Q: Does Dobetin need to be taken at a specific time of day?

A: The official administration schedule focuses on the required frequency (e.g., daily or monthly), and does not typically mandate a specific time of day for the injection to be administered.

Q: Is it normal to feel a mild stomach upset with Dobetin?

A: Official adverse reaction lists do include the documented occurrence of 'mild transient diarrhea' under gastrointestinal disorders. This means temporary diarrhea is a documented side effect.

Q: Does Dobetin affect blood sugar levels?

A: The medicine itself is not generally documented in official sources to directly alter blood glucose levels. However, a known drug interaction exists with the diabetes medicine Metformin, which can cause decreased Vitamin B12 levels in the body.

Q: How long does Dobetin stay in your system after the last dose?

A: Regulatory information on the medicine’s movement within the body (pharmacokinetics) indicates that after injection, the vitamin is rapidly absorbed, with maximum levels in the bloodstream reached quickly. The liver is the primary storage site for the vitamin in the body.

Q: Are there different forms of Dobetin (e.g., tablet, injection, liquid)?

A: The active ingredient, Cyanocobalamin, is manufactured in various forms. These include the injectable solution, oral tablets, and nasal sprays, with the chosen form dependent on the patient's specific absorption capacity.

Q: Why is Dobetin used alongside other medicines in some cases?

A: Regulatory guidance specifies that this medicine may be administered alongside other treatments, such as Folic Acid. This is done because taking B12 alone could potentially mask the diagnosis of an underlying folate deficiency.

Q: Are there studies comparing Dobetin use in different age groups?

A: Regulatory documents confirm the established use of the medicine for both adult and pediatric populations, noting that the standard adult dosage schedules are considered suitable for children.

Q: Does Dobetin have any mood-related side effects?

A: Official side effect listings include reactions affecting the central nervous system, such as severe dizziness, which are typically listed as rare or with unknown frequency.

Q: Is there a warning about using Dobetin with products containing iron?

A: Regulatory documents indicate that the pharmacological activity of Cyanocobalamin is noted to be destroyed by heavy metals, a category which includes iron.

Q: Is Dobetin available over the counter in some countries?

A: The injection form of the medicine is a prescription-only product. However, the active ingredient Cyanocobalamin is widely available in oral forms as a dietary supplement that can be purchased over-the-counter.

Q: Are there any known withdrawal symptoms associated with stopping Dobetin?

A: Official documents do not describe a specific pharmacological withdrawal syndrome. Since the medicine is essential for maintenance, abruptly stopping treatment may result in the recurrence of the underlying Vitamin B12 deficiency symptoms.

Q: Does Dobetin interact with birth control pills?

A: Official sources note that hormonal contraceptives may be associated with falsely low laboratory measurements of Vitamin B12 levels, which is considered a diagnostic constraint.

Q: What is the main difference between the dosage forms of Dobetin?

A: The differences between the dosage forms, such as the injection versus an oral tablet, are primarily related to the route of administration. The choice depends on the patient's condition, particularly their ability to absorb the vitamin naturally.

Q: Does taking Dobetin require regular blood tests?

A: Regulatory guidance indicates that monitoring of certain laboratory tests, such as serum Vitamin B12 levels and potassium, is advised closely, especially during the initial phase of treatment.

Q: Are there any dietary restrictions specifically mentioned for Dobetin use?

A: A mandatory timing constraint exists only for high doses of Vitamin C (ascorbic acid), where official guidance indicates separation by at least one hour from oral forms of B12 due to the potential for destruction of the vitamin.

Q: Are headaches a common initial side effect of Dobetin?

A: Headache is noted in authoritative side effect listings, although official documents often list its frequency as unknown or less common.

How should Dobetin be stored and disposed of?

How to Store and Dispose of Dobetin?

Regulatory labeling requires specific conditions for the storage and final disposal of Dobetin (Cyanocobalamin Solution for Injection).


Storage Requirements

Requirement Official Statement
Temperature Store below 25 C in a fresh and dry place
Protection Must be stored away from light
Child Safety Keep out of the reach of children

Stability and Disposal

The product's shelf-life after the immediate packaging is first opened is limited to 28 days. All unused or expired product and related waste materials must be disposed of strictly according to local requirements for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dobetin  found in:

A-Z Index: